Amelia Toesca

Amelia Toesca

Auto-generated profile, based on publicly available information

Amelia Toesca

Institute of Anatomy and Cell Biology, Università Cattolica del Sacro Cuore, Rome, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2018 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
Fabrizio MichettiFabrizio Michetti
Fabrizio Michetti
Nadia D'AmbrosiNadia D'Ambrosi
Nadia D'Ambrosi
ATAmelia Toesca
Amelia Toesca
MPMaria Ausiliatrice Puglisi
Maria Ausiliatrice Puglisi
ASAlessia Serrano
Alessia Serrano
MGMaria Concetta Geloso
Maria Concetta Geloso
S100B is a Ca2+‐binding protein mainly concentrated in astrocytes. Its levels in biological fluids (cerebrospinal fluid, peripheral and cord blood, urine, saliva, amniotic fluid) are recognized as a reliable biomarker of active neural distress. Although the wide spectrum of diseases in which the protein is involved (acute brain injury, neurodegenerative diseases, congenital/perinatal disorders, psychiatric disorders) reduces its specificity, its levels remain an important aid in monitoring the trend of the disorder. Mounting evidence now points to S100B as a Damage‐Associated Molecular Pattern molecule which, when released at high concentration, through its Receptor for Advanced Glycation Endproducts, triggers tissue reaction to damage in a series of different neural disorders. This review addresses this novel scenario, presenting data indicating that S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease: acute brain injury (ischemic/hemorrhagic stroke, traumatic injury), neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis), congenital/perinatal disorders (Down syndrome, spinocerebellar ataxia‐1), psychiatric disorders (schizophrenia, mood disorders), inflammatory bowel disease. In many cases, over‐expression/administration of the protein induces worsening of the disease, whereas its deletion/inactivation produces amelioration. This review points out that the pivotal role of the protein resulting from these data, opens the perspective that S100B may be regarded as a therapeutic target for these different diseases, which appear to share some common features reasonably attributable to neuroinflammation, regardless their origin. image

1 May 2004 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
DGDiego Gazzolo
Diego Gazzolo
DGDariusz Grutzfeld
Dariusz Grutzfeld
FMFabrizio Michetti
Fabrizio Michetti
ATAmelia Toesca
Amelia Toesca
MLMario Lituania
Mario Lituania
PBPierluigi Bruschettini
Pierluigi Bruschettini